RxDoctor Payments Data

Amanda Brown-Bartlett

Family · Plainfield, ILNPI 1235665076

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 41.8% of the total. That places this record below the midpoint for family clinicians in IL, where the typical reported total is $284.

$316in general payments, 2019–2025

Across 16 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$132
  • AstraZeneca$86
  • Pfizer$31
  • Astellas Pharma US Inc$19
  • Johnson & Johnson$17
  • Novo Nordisk$16
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$316 in reported general payments places this provider in the 50th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$29,348
Medicare patients
114
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$59,074
JardianceEmpagliflozin13$15,812
TradjentaLinagliptin18$15,065
MyrbetriqMirabegron13$6,317
XareltoRivaroxaban15$6,067
RytaryCarbidopa/Levodopa12$6,005
Budesonide EcBudesonide12$4,733
Potassium Chloride226$3,668
Atorvastatin Calcium236$3,339
Memantine Hcl84$3,139
Tolterodine Tartrate ErTolterodine Tartrate25$3,031
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$2,943
Metoprolol Succinate196$2,510
Divalproex Sodium19$2,300
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen67$2,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$59,07498 claims
Astellas Pharma US IncMyrbetriq$19$6,31713 claims
Johnson & JohnsonXarelto$17$6,06715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,941 family providers in Illinois.

Other family in Plainfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →